Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting.
Summary of "Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting."
Although nausea and vomiting occur in patients with cancer for various reasons, chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing symptoms associated with cancer therapy. Despite advances in the management of that side effect, patients with cancer receiving chemotherapy continue to report CINV. Oncology nurses should be aware of advances in the management of CINV. Healthcare provider perceptions of CINV may not accurately represent actual occurrence of the symptom, and CINV may affect patients' quality of life or even treatment adherence for selected patients. Although evidence-based guidelines are available, not all healthcare providers, including oncology nurses, follow recommendations for prevention of CINV. Inadequately treated CINV can lead to increased resource costs, as well as patient suffering. This article will review the evidence for the cost of inadequately treated CINV, as well as current clinical guidelines for management of this symptom. Oncology nurses are critical in the assessment and management of CINV, as well as in making recommendations for practice improvement.
Affiliation
Oncology Nurse Practitioner and Consultant, Goleta, CA.
Journal Details
This article was published in the following journal.
Name: Clinical journal of oncology nursing
ISSN: 1538-067X
Pages: E133-41
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22842698
- DOI: http://dx.doi.org/10.1188/12.CJON.E133-E141
Medical and Biotech [MESH] Definitions
Ondansetron
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Thiethylperazine
A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457)
Dimenhydrinate
A drug combination that contains DIPHENHYDRAMINE and THEOPHYLLINE. It is used for treating vertigo, motion sickness, and nausea associated with pregnancy. It is not effective in the treatment of nausea associated with cancer chemotherapy.
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. Antiemetics act by a wide range of mechanisms. Some act on the medullary control centers (the vomiting center and the chemoreceptive trigger zone) while others affect the peripheral receptors.
Morning Sickness
Symptoms of NAUSEA and VOMITING in pregnant women that usually occur in the morning during the first 2 to 3 months of PREGNANCY. Severe persistent vomiting during pregnancy is called HYPEREMESIS GRAVIDARUM.
PubMed Articles
Treatment of Chemotherapy-Induced Nausea and Vomiting.
BACKGROUND: Recent improvements in medical oncology include both development of anticancer and supportive therapy. Serotonin receptor antagonists were introduced in clinical practice 20 years ago. Sin...
INTRODUCTION: The goal of pharmacological prophylaxis of chemotherapy-induced nausea and vomiting (CINV) should be the elimination of both nausea and vomiting symptoms during all planned chemotherapy...
AIMS AND OBJECTIVES: To reveal the effects of music therapy and visual imagery on chemotherapy-induced anxiety and nausea-vomiting. BACKGROUND: Behavioural techniques such as music therapy and visual...
Chemotherapy-induced nausea and vomiting is one of the most concerning adverse drug effects from cytotoxic chemotherapy. Despite appropriate use of antiemetic guidelines, 20-30 % of patients experien...
Anticipatory nausea and vomiting.
A commonly reported consequence of post-treatment nausea or vomiting is the development of anticipatory nausea and vomiting (ANV). In most published work, nausea is reported to occur before chemothera...
Clinical Trials
This study is designed to assess the safety and efficacy of palonesetron in preventing CINV (Chemotherapy-Induced Nausea and Vomiting) when administered to patients who have experienced ei...
This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.
Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients
The study drug, Aprepitant, is currently used to control chemotherapy induced nausea and vomiting and is also approved for post-operative nausea and vomiting. The investigators' evaluation...
Fosaprepitant for Breakthrough Chemotherapy Induced Nausea and Vomiting
The purpose of this study is to test the safety and effectiveness of fosaprepitant. The investigators want to find out what effects, good and/or bad, it has on chemotherapy induced nausea...
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and...
